The group's principal activity is to conduct research and develop biopharmaceutical products for treatment of cancer treatment agents (vtas), ocular diseases. These agents attack a tumor's network of existing and emerging blood vessels, which are its main life support system. The group is also investigating products for other applications in the field of ophthalmology in particular age-related macular degeneration and myopic macular degeneration. The group provides clinical and pre-clinical development, multiple therapeutic product candidates that were derived from its principal vascular targeting platform. The group has collaborative agreements with a number of academic and research institutions and organizations in the United States and abroad.
Executive Information
Name
Title
Email
Joel Citron
Chmn.
N/A
Richard Chin
Dir., CEO, Pres.
N/A
David Chaplin
Vice Chmn., Chief Scientific Officer, Head - Research, Development
